In a recent announcement on Friday afternoon, Pfizer (NYSE: PFE), the world's largest pharmaceutical company, revealed the discontinuation of a two-day obesity drug trial, leading to a sharp decline in its shares by over 6%. The drug, named danuglipron, faced termination due to reported side effects observed in a previous study, causing Pfizer's stocks to plummet by 44.2% since the beginning of the year.
Pfizer Abandons Obesity Drug Trial Amidst Adverse Effects:
The decision by Pfizer to forego the Phase 3 trials of its obesity drugs, formulated for twice-daily administration, stemmed from the numerous adverse effects experienced by participants in an earlier study. The company cited the drug, danuglipron, and its discontinued trial due to the side effects emerging from a Phase 2b study, indicating statistically significant weight loss compared to a placebo.
"Danuglipron demonstrated weight reductions ranging from -8% to -13% over 32 weeks and -5% to -9.5% over 26 weeks compared to placebo," stated Pfizer in a press release.
Market Response: Pfizer Stocks Experience Sharp Decline:
As the news broke, Pfizer's shares experienced a rapid decline, reaching $28.58 and marking a nearly 45% loss since the beginning of the year. This downturn is attributed to a swift decrease in sales, driven by a decline in demand for Pfizer's COVID-19 products amid the global post-pandemic recovery. The company reported losses in Q3 due to challenges surrounding its COVID-19 vaccine and antiviral treatment, Paxlovid.
Ongoing Trends in Obesity Drugs: Novo Nordisk and Eli Lilly Lead the Way:
While Pfizer faces setbacks, the market for obesity and diabetes treatments continues to evolve, with Novo Nordisk and Eli Lilly at the forefront. Novo Nordisk's Wegovy, Eli Lilly's Ozempic, and Mounjaro have set a trend with injectable medications that mimic the effects of a gut hormone to regulate appetite and blood sugar.
Novo Nordisk's Success with Wegovy and Ozempic: Novo Nordisk's Wegovy and Ozempic have been key drivers of the company's growth, with their shares rising by 48% and 64.31%, respectively. These GLP-1 receptor agonists have gained approval in the United States for the treatment of type 2 diabetes, showcasing their effectiveness in managing both diabetes and obesity.Eli Lilly's Mounjaro and Zepbound, and the FDA Approval for Weight Management: Eli Lilly's Mounjaro, similar to Novo Nordisk's Ozempic, and Zepbound, akin to Mounjaro, have received approval from the U.S. Food and Drug Administration (FDA) not only for the treatment of type 2 diabetes but also for weight management. This dual approval positions these medications as versatile solutions for patients struggling with both conditions.

While Pfizer grapples with the discontinuation of its obesity drug trial, competitors Novo Nordisk and Eli Lilly continue to thrive in the evolving landscape of obesity and diabetes treatments. The industry's focus on innovative solutions reflects a commitment to addressing the complex challenges of these prevalent health conditions, providing hope for improved outcomes for patients in the future.
#Pfizer #NYSE #PFE #COVID-19

The New York Stock Exchange (NYSE) is reportedly getting a gauge on whether traders would embrace 24-hour stock trading, similar to how cryptocurrency markets operate.
To test market sentiment, NYSE’s data analytics team put out a survey asking market participants whether they would support 24/7 or 24-hour weekday trading and if so, what systems should be put in place to protect traders from overnight price swings, according to an April 22 report from the Financial Times.
NYSE — along with the Nasdaq and Chicago Board Options Exchange — currently trade Monday to Friday between 9:30 am to 4:00 pm Eastern Time.
In the United States, assets such as cryptocurrencies, United States Treasurys, foreign exchange and leading stock index futures can already be traded 24/7, while some brokerages offer 
Robinhood and Interactive Brokers are such platforms, offering 24-hour weekday access to U.S. stocks by facilitating a “dark pool” trading venue allowing international retail investors to trade shares during their daytime hours.
However, last week, reports emerged that Robinhood halted its 24-hour trading services following increased tensions between Israel and Iran, raising investor concerns about the sustainability of around-the-clock trading.
Managing liquidity in a 24/7 trading arena has al proven a tough task for trading platforms in the cryptocurrency industry.
It often creates a “mismatch between the operating hours of traditional financial institutions and the needs of large crypto traders and market makers,” noted cryptocurrency research firm Kaiko. Sleepless nights are a common complaint for traders when the market becomes extremely volatile too.
While results of NYSE's poll haven’t been released, Skylands Capital senior trader Tom Hearden posted a poll of his own asking his 19,300 X followers whether they would support NYSE moving to 24/7 trading hours — with over 70% of the 1,459 respondents voting “No.”

NYSE’s poll comes as startup firm 24X National Exchange is seeking approval from the Securities and Exchange Commission (SEC) to launch the first round-the-clock exchange in the country.
The SEC still has “months” to review the requested rule change, while other stakeholders involved are already looking at pertinent issues, such as who should bear costs and the role of clearing houses, FT said, citing two sources familiar with the matter.
“I have no idea how much volume they’re going to be doing in the middle of the night. But it’s really not up to the SEC to decide whether it’s commercially viable or not,” said James Angel, a finance professor at Georgetown University to FT.
“I’m in favour of letting the market decide. If it succeeds, we’re all better off and if it doesn’t, well, the exchange’s investors lost.”
It marks the second attempt at SEC approval after the firm withdrew a proposal in March 2023, citing operations and technical issues.
#Crypto #Cryptocurrency #NYSE